Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017.

Authors

Peter Doshi
O'Mareen Spence
Aida Kuzucan
John H Powers, George Washington University

Document Type

Journal Article

Publication Date

3-4-2019

Journal

JAMA Internal Medicine

DOI

10.1001/jamainternmed.2018.7040

Comments

Epub ahead of print

APA Citation

Doshi, P., Spence, O., Kuzucan, A., & Powers, J. (2019). Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017.. JAMA Internal Medicine, (). http://dx.doi.org/10.1001/jamainternmed.2018.7040

Peer Reviewed

1